Editing Gates Foundation (section)

==Global health division==
Since 2011, the president of the Global Health Program is [[Trevor Mundel]]:<ref>{{cite web |title=Leadership – Trevor Mundel |url=http://www.gatesfoundation.org/Who-We-Are/General-Information/Leadership/Management-Committee/Trevor-Mundel |work=Bill & Melinda Gates Foundation |access-date=April 6, 2014 |year=2014 |url-status=dead |archive-url=https://web.archive.org/web/20140407090436/http://www.gatesfoundation.org/Who-We-Are/General-Information/Leadership/Management-Committee/Trevor-Mundel |archive-date=April 7, 2014 }}</ref>
* [[The Global Fund to Fight AIDS, Tuberculosis and Malaria]]: The foundation has donated more than $6.6 billion for global health programs, including over $1.3 billion donated as of 2012 on [[malaria]] alone, greatly increasing the dollars spent per year on malaria research.<ref name="garrett gates">[http://www.foreignaffairs.org/20070101faessay86103/laurie-garrett/the-challenge-of-global-health.html The Challenge of Global Health] {{webarchive |url=https://web.archive.org/web/20070109083214/http://www.foreignaffairs.org/20070101faessay86103/laurie-garrett/the-challenge-of-global-health.html |date=January 9, 2007 }} Foreign Affairs, January/February 2007</ref><ref name="ReferenceB">{{cite web |url=https://www.nytimes.com/2008/02/16/science/16malaria.html |title=Gates Foundation's Influence Criticized |date=February 16, 2008 |work=The New York Times |access-date=December 17, 2016 |archive-date=April 8, 2023 |archive-url=https://web.archive.org/web/20230408175726/https://www.nytimes.com/2008/02/16/science/16malaria.html |url-status=live }}</ref> Before the Gates efforts on malaria, malaria drugmakers had largely given up on producing drugs to fight the disease, and the foundation is the world's largest donor to research on diseases of the poor.<ref name="ReferenceB"/> With the help of Gates-funded vaccination drives, deaths from [[measles]] in Africa have dropped by 90 percent since 2000.<ref name="LA">{{Cite news |last1=Piller |first1=Charles |last2=Smith |first2=Doug |title=Unintended victims of Gates Foundation generosity |newspaper=[[Los Angeles Times]] |date=December 16, 2007 |url=https://www.latimes.com/nation/la-xpm-2007-dec-16-la-na-gates16dec16-story.html |access-date=March 23, 2020 |archive-date=March 23, 2020 |archive-url=https://web.archive.org/web/20200323115345/https://www.latimes.com/nation/la-xpm-2007-dec-16-la-na-gates16dec16-story.html |url-status=live }}</ref>

The foundation has donated billions of dollars to help sufferers of [[AIDS]], [[tuberculosis]] and malaria, protecting millions of children from death at the hands of preventable diseases.<ref name="LA"/>

The Global Health Program's other significant grants include:
* [[Poliomyelitis eradication|Polio eradication]]: In 2006, the foundation provided $86 million toward efforts attempting to eradicate [[poliomyelitis]] (polio).<ref>{{cite web|url=http://www.polioeradication.org/content/general/HistContributionWebMay06.pdf| title=Donor Contributions to the Global Polio Eradication Initiative, 1985-2008 |archive-url=https://web.archive.org/web/20080414095646/http://www.polioeradication.org/content/general/HistContributionWebMay06.pdf|archive-date=2008-04-14 |date=April 14, 2008}}</ref>
* The [[GAVI]] vaccine alliance: The foundation gave the GAVI Alliance (formerly the "Global Alliance for Vaccines and Immunization") a donation of $750 million on January 25, 2005.<ref>{{cite press release |title=Gates Foundation, Norway Contribute $1 Billion to Increase Child Immunization in Developing Countries |author=[[GAVI]] |date=January 24, 2005 |url=http://www.gavialliance.org/media_centre/press_releases/2005_01_24_en_pr_newfunds.php |access-date=October 24, 2007 |archive-url=https://web.archive.org/web/20071013063234/http://www.gavialliance.org/media_centre/press_releases/2005_01_24_en_pr_newfunds.php |archive-date=October 13, 2007| url-status=live}}</ref><ref>{{cite web |last=Thomson |first=Iain |title=Bill Gates gives $750m to help African children |date=January 25, 2005 |url=http://www.vnunet.com/vnunet/news/2126576/bill-gates-gives-750m-help-african-children |access-date=October 24, 2007 |archive-url=https://web.archive.org/web/20071102051550/http://www.vnunet.com/vnunet/news/2126576/bill-gates-gives-750m-help-african-children |archive-date=November 2, 2007|url-status=dead }}</ref>
* Children's Vaccine Program: The Children's Vaccine Program, run by the [[Program for Appropriate Technology in Health]] (PATH), received a donation of $27 million to help vaccinate against [[Japanese encephalitis]] on December 9, 2003.<ref>{{cite press release |title=Children's Vaccine Program Receives Grant From Bill & Melinda Gates Foundation to Combat Japanese Encephalitis |publisher=[[Program for Appropriate Technology in Health]] |date=December 9, 2003 |url=http://childrensvaccine.org/html/rel-031209.htm |archive-url=https://web.archive.org/web/20031221215749/http://childrensvaccine.org/html/rel-031209.htm |archive-date=December 21, 2003 |access-date=October 24, 2007}}</ref>
* HIV Research: The foundation donated a total of $287 million to various [[HIV/AIDS]] researchers. The money was split between 16 different research teams across the world, on the condition that the findings are shared amongst the teams.<ref>{{cite news |work=BBC News |title=Gates gives $287m to HIV research |date=July 20, 2006 |url=http://news.bbc.co.uk/1/hi/world/americas/5197082.stm |access-date=October 24, 2007 |archive-date=February 11, 2007 |archive-url=https://web.archive.org/web/20070211070748/http://news.bbc.co.uk/1/hi/world/americas/5197082.stm |url-status=live }}</ref>
* [[Aeras Global TB Vaccine Foundation]]: The foundation gave the Aeras Global TB Vaccine Foundation more than $280 million to develop and license an improved vaccine against tuberculosis (TB) for use in [[Disease burden|high-burden countries]] (HBCs).<ref>{{cite web |title=Gates Foundation Commits $82.9 Million to Develop New Tuberculosis Vaccines |date=February 12, 2004 |url=http://www.globalhealth.org/news/article/4134 |url-status=dead |archive-url=https://web.archive.org/web/20091010163118/http://www.globalhealth.org/news/article/4134 |archive-date=October 10, 2009 }}</ref><ref>{{cite web |last=Nightingale |first=Katherine |title=Gates foundation gives US$280 million to fight TB |date=September 19, 2007 |url=http://www.scidev.net/en/news/gates-foundation-gives-us280-million-to-fight-tb.html |access-date=February 3, 2009 |archive-date=December 1, 2008 |archive-url=https://web.archive.org/web/20081201175618/http://www.scidev.net/en/news/gates-foundation-gives-us280-million-to-fight-tb.html |url-status=live }}</ref>
* Cheaper high-tech tuberculosis (TB) test: In August 2012, the foundation, in partnership with [[President's Emergency Plan for AIDS Relief|PEPFAR]] (United States President's Emergency Plan for AIDS Relief), [[United States Agency for International Development|USAID]] (United States Agency for International Development) and [[UNITAID]] (an international drug purchasing facility hosted by WHO), announced they had finalized an agreement to reduce the cost of a commercial TB test (Cepheid's Xpert MTB/RIF run on the [[GeneXpert MTB/RIF|GeneXpert platform]]), from $16.86 to $9.98.<ref>{{cite web |title=Negotiated prices for Xpert® MTB/RIF and FIND country list |url=http://www.finddiagnostics.org/about/what_we_do/successes/find-negotiated-prices/xpert_mtb_rif.html |work=FIND Diagnostics |publisher=FIND |access-date=April 6, 2014 |date=October 2013|url-status=dead |archive-url=https://web.archive.org/web/20140407082202/http://www.finddiagnostics.org/about/what_we_do/successes/find-negotiated-prices/xpert_mtb_rif.html |archive-date=April 7, 2014 }}</ref> This test can take the place of smear microscopy, a technique first developed in the 1880s by Robert Koch. Smear microscopy often does not show TB infection in persons who are also co-infected with HIV, whereas the GeneXpert system can show TB in the co-infected patient. In addition, the system can show whether the particular TB strain is resistant to the [[bactericidal]] antibiotic [[rifampicin]], a widely accepted indicator of the presence of multidrug resistant tuberculosis.<ref>{{cite web |title=Public-Private Partnership Announces Immediate 40 Percent Cost Reduction for Rapid TB Test |url=https://www.who.int/tb/features_archive/GeneXpert_press_release_final.pdf |work=World Health Organization |publisher=United Nations |access-date=April 6, 2014 |date=August 6, 2012 |archive-date=October 29, 2013 |archive-url=https://web.archive.org/web/20131029234310/http://www.who.int/tb/features_archive/GeneXpert_press_release_final.pdf |url-status=live }}</ref><ref>{{cite web |title=Published evidence and commentary on the Xpert MTB/RIF assay |url=http://www.stoptb.org/wg/gli/assets/documents/map/XpertPublications.pdf |work=Stop TB Partnership |publisher=World Health Organization |access-date=April 6, 2014 |date=March 12, 2014 |archive-date=January 24, 2014 |archive-url=https://web.archive.org/web/20140124041952/http://www.stoptb.org/wg/gli/assets/documents/map/XpertPublications.pdf |url-status=live }}</ref>
* [[Visceral leishmaniasis]] (VL) research: The foundation awarded the [[Hebrew University of Jerusalem]]'s Kuvin Center for the Study of Infectious and Tropical Diseases a $5 million grant in 2009 for research into visceral leishmaniasis (VL), an emerging parasitic disease in [[Ethiopia]], Africa, where it is frequently associated with HIV/AIDS and is a leading cause of adult illness and death. The project, a collaborative effort with [[Addis Ababa University]], will gather data for analysis—to identify the weak links in the transmission cycle—and devise methods for control of the disease.<ref>{{cite news |title=$5 m for disease control in Ethiopia |url=http://www.israel21c.org/briefs/5-m-for-disease-control-in-ethiopia |access-date=April 6, 2014 |newspaper=Israel21C |date=December 30, 2009 |archive-date=February 29, 2012 |archive-url=https://web.archive.org/web/20120229163040/http://www.israel21c.org/briefs/5-m-for-disease-control-in-ethiopia |url-status=live }}</ref> In 2005 the foundation provided a $30 million grant to [[The Institute for OneWorld Health]] to support the nonprofit pharmaceutical company's VL work in the rural communities of India, Bangladesh and Nepal.<ref>{{cite web |title=Institute for OneWorld Health receives multimillion dollar grant |url=http://www.eurekalert.org/pub_releases/2005-12/ifoh-ifo113005.php |work=EurekAlert! |publisher=AAAS and EurekAlert! |access-date=April 6, 2014 |date=December 1, 2005 |archive-date=July 26, 2024 |archive-url=https://web.archive.org/web/20240726173438/https://www.eurekalert.org/news-releases/550055 |url-status=live }}</ref> By September 2006, the company had received approval from the Indian body Drug-Controller General of India (DCGI) for the Paromomycin Intramuscular (IM) Injection, a drug that provides an effective cure for VL following a 21-day course.<ref>{{cite web |title=New Cure for Deadly Visceral Leishmaniasis (Kala-Azar) Approved by Government of India, Institute for OneWorld Health and Gland Pharma Limited Achieve Critical Paromomycin Milestone |url=http://businesswireindia.com/news/news-details/new-cure-deadly-visceral-leishmaniasis-kala-azar-approved-by-governmen/10736 |work=Business Wire India |access-date=April 6, 2014 |date=September 14, 2008 |archive-date=April 7, 2014 |archive-url=https://web.archive.org/web/20140407080356/http://businesswireindia.com/news/news-details/new-cure-deadly-visceral-leishmaniasis-kala-azar-approved-by-governmen/10736 |url-status=live }}</ref> In 2010 Raj Shankar Ghosh, the Regional Director for the South Asia Institute for OneWorld Health, explained that the foundation funded "the majority of our work" in the development of the drug.<ref>{{cite web |title=Q & A: Institute for OneWorld Health |url=https://www.landesbioscience.com/journals/virulence/OneWorldVir.pdf |work=Access Granted Rita. |publisher=Landes Bioscience |access-date=April 6, 2014 |first=Kyle |last=Funk |date=September–October 2010 |url-status=dead |archive-url=https://web.archive.org/web/20140407085007/https://www.landesbioscience.com/journals/virulence/OneWorldVir.pdf |archive-date=April 7, 2014 }}</ref>
* [[Group B streptococcus]]: The foundation gave $17,252,854 in September 2016 to [[Pfizer]] to develop a vaccine against Group B streptococcus (GBS) for distribution in developing countries.<ref>{{Cite web |date=September 2016 |title=Pfizer Inc. |url=https://www.gatesfoundation.org/about/committed-grants/2016/09/opp1133548 |url-status=live |archive-url=https://archive.today/20210710054331/https://www.gatesfoundation.org/about/committed-grants/2016/09/opp1133548 |archive-date=2021-07-10 |access-date=2022-06-14 |website=Bill & Melinda Gates Foundation |language=en}}</ref> In May 2022, the funding was renewed with an additional $100,000,000.<ref>{{Cite web |date=May 2022 |title=Pfizer Inc. |url=https://www.gatesfoundation.org/about/committed-grants/2022/05/inv044719 |access-date=2022-06-14 |website=Bill & Melinda Gates Foundation |language=en |archive-date=June 14, 2022 |archive-url=https://web.archive.org/web/20220614004212/https://www.gatesfoundation.org/about/committed-grants/2022/05/inv044719 |url-status=dead }}</ref>
* Next-Generation Condom: The foundation gave $100,000 to 11 applicants in November 2013 to develop an improved condom; that is, one that "significantly preserves or enhances pleasure, in order to improve uptake and regular use", according to the Gates Foundation's [[Grand Challenges in Global Health]] website.<ref>{{cite web |title=TOPIC: Develop the Next Generation of Condom |url=http://www.grandchallenges.org/Explorations/Topics/Pages/NextGenerationCondomRound11.aspx |work=Grand Challenges in Global Health |access-date=April 6, 2014 |date=March 2013 |archive-date=April 7, 2014 |archive-url=https://web.archive.org/web/20140407023640/http://www.grandchallenges.org/explorations/topics/pages/nextgenerationcondomround11.aspx |url-status=dead }}</ref> Further grants of up to $1 million will be given to projects that are successful.<ref>{{cite news |title=Innovation: Next-Gen Condoms |url=http://images.businessweek.com/slideshows/2013-12-05/innovation-next-gen-condoms |archive-url=https://web.archive.org/web/20131206122610/http://images.businessweek.com/slideshows/2013-12-05/innovation-next-gen-condoms |url-status=dead |archive-date=December 6, 2013 |access-date=April 6, 2014 |newspaper=Bloomberg Businessweek |date=December 5, 2013 |first=Nick |last=Lieber}}</ref>
* [[Neglected tropical diseases]] (NTDs): Alongside WHO, the governments of the United States, United Kingdom and United Arab Emirates, and the World Bank, the foundation endorsed the [[London Declaration on Neglected Tropical Diseases]], "to eradicate, eliminate and intensify control of 17 selected diseases by 2015 and 2020", at a meeting on January 30, 2012, held at the Royal College of Physicians in London, UK.<ref>{{cite web |title=WHO roadmap inspires unprecedented support to defeat neglected tropical diseases |url=https://www.who.int/neglected_diseases/London_meeting_follow_up/en/ |archive-url=https://web.archive.org/web/20140407075831/http://www.who.int/neglected_diseases/London_meeting_follow_up/en/ |url-status=dead |archive-date=April 7, 2014 |work=World Health Organization |publisher=WHO |access-date=April 6, 2014 |date=February 3, 2012}}</ref> Gates was the principal organizer responsible for bringing together the heads of 13 of the world's largest pharmaceutical companies and the foundation's monetary commitment to the Declaration was $363 million over five years.<ref>{{cite news |title=Drug companies join forces to combat deadliest tropical diseases |url=https://www.theguardian.com/global-development/2012/jan/30/drug-companies-join-tropical-diseases |access-date=April 6, 2014 |newspaper=The Guardian |date=January 30, 2012 |first=Sarah |last=Boseley |archive-date=July 26, 2024 |archive-url=https://web.archive.org/web/20240726173940/https://www.theguardian.com/global-development/2012/jan/30/drug-companies-join-tropical-diseases |url-status=live }}</ref> On April 3, 2014, the second anniversary of the Declaration, Gates attended a meeting in [[Paris]] at which participants reviewed the progress that had been made against 10 neglected tropical diseases (NTDs). The foundation committed a further $50 million, together with $50 million from the [[Children's Investment Fund Foundation]] and $120 million from the World Bank.<ref>{{cite news |title=Bill Gates: world must step up fight against neglected tropical diseases |url=https://www.theguardian.com/society/2014/apr/03/bill-gates-world-must-fight-tropical-diseases |access-date=April 6, 2014 |newspaper=The Guardian |date=April 4, 2014 |first=Sarah |last=Boseley |archive-date=July 26, 2024 |archive-url=https://web.archive.org/web/20240726173942/https://www.theguardian.com/society/2014/apr/03/bill-gates-world-must-fight-tropical-diseases |url-status=live }}</ref> The foundation has given in excess of $1 million to The END Fund, a public-private partnership to deliver medication for NTDs to areas in need.<ref>{{Cite web |date=2017-11-09 |title=END Fund Partners |url=https://end.org/who-we-are/partners/ |url-status=live |archive-url=https://web.archive.org/web/20220215194305/https://end.org/who-we-are/partners/ |archive-date=2022-02-15 |access-date=2022-06-06 |website=The END Fund |language=en-US}}</ref>
* [[Monoclonal antibody therapy|Monoclonal antibody therapies]]: In October 2018, the foundation awarded $8,279,723 to [[Inovio Pharmaceuticals]] to fund the development of "next-generation" delivery methods for [[Monoclonal antibody|monoclonal antibodies]] targeted for use in low- and middle-income countries.<ref>{{Cite web |title=Inovio Pharmaceuticals, Inc. |url=https://www.gatesfoundation.org/about/committed-grants/2018/10/opp1201239 |url-status=live |archive-url=https://archive.today/20220614004812/https://www.gatesfoundation.org/about/committed-grants/2018/10/opp1201239 |archive-date=2022-06-14 |access-date=2022-06-14 |website=Bill & Melinda Gates Foundation |language=en}}</ref>
* [[Coalition for Epidemic Preparedness Innovations]] (CEPI): A global group tasked with more quickly developing [[vaccine]]s against infectious disease threats worldwide was launched on January 8, 2017, by a coalition of governments and nonprofit groups including the Bill & Melinda Gates Foundation. The Coalition for Epidemic Preparedness Innovations, funded with an initial investment of $460 million from [[Germany]], [[Japan]], [[Norway]], the [[Wellcome Trust]] and the Gates foundation, aims to develop [[vaccine]]s against known infectious disease threats that could be deployed quickly to contain outbreaks before they become global health emergencies, the group said in a statement at the [[World Economic Forum]] in [[Davos|Davos, Switzerland]].<ref>{{Cite news |url=https://www.bloomberg.com/news/articles/2017-01-18/gates-foundation-joins-new-460-million-coalition-for-vaccines |title=Gates Foundation Joins New $460 Million Coalition for Vaccines |date=January 18, 2017 |newspaper=Bloomberg.com |access-date=January 19, 2017 |archive-date=July 26, 2024 |archive-url=https://web.archive.org/web/20240726174445/https://www.bloomberg.com/news/articles/2017-01-18/gates-foundation-joins-new-460-million-coalition-for-vaccines |url-status=live }}</ref><ref>{{Cite web|url=https://wellcome.ac.uk/news/global-fund-outsmart-epidemics|title=Global fund to outsmart epidemics {{!}} Wellcome|website=wellcome.ac.uk|language=en|access-date=January 19, 2017|archive-date=January 25, 2017|archive-url=https://web.archive.org/web/20170125155059/https://wellcome.ac.uk/news/global-fund-outsmart-epidemics|url-status=live}}</ref>
* [https://www.who.int/news/item/24-04-2023-global-partners-announce-a-new-effort-the-big-catch-up-to-vaccinate-millions-of-children-and-restore-immunization-progress-lost-during-the-pandemic The Big Catch-up]: In response to the decline in childhood vaccination rates affecting over 100 countries due to the COVID-19 pandemic, global health partners including WHO, UNICEF, Gavi, and the Vaccine Alliance launched "The Big Catch-up" initiative. This collaborative effort aims to reverse vaccination declines, particularly in 20 countries with the highest numbers of missed vaccinations. Over 25 million children missed at least one vaccination in 2021, leading to preventable disease outbreaks. The initiative focuses on strengthening healthcare systems, building trust in vaccines, and addressing barriers to immunization, with an emphasis on reaching vulnerable populations.<ref>{{Cite web |title=Global partners announce a new effort – "The Big Catch-up" – to vaccinate millions of children and restore immunization progress lost during the pandemic |url=https://www.who.int/news/item/24-04-2023-global-partners-announce-a-new-effort-the-big-catch-up-to-vaccinate-millions-of-children-and-restore-immunization-progress-lost-during-the-pandemic |access-date=2023-09-28 |website=www.who.int |language=en |archive-date=September 23, 2023 |archive-url=https://web.archive.org/web/20230923110134/https://www.who.int/news/item/24-04-2023-global-partners-announce-a-new-effort-the-big-catch-up-to-vaccinate-millions-of-children-and-restore-immunization-progress-lost-during-the-pandemic |url-status=live }}</ref> 

=== COVID-19 ===
Beginning in 2020, the Bill & Melinda Gates Foundation has provided hundreds of millions of dollars of funding towards initiatives surrounding the [[COVID-19 pandemic|COVID-19 public health crisis]].

==== COVID-19 Therapeutics Accelerator ====
In 2020, together with the UK research charity [[Wellcome]] and [[Mastercard International Global Headquarters|Mastercard]], the Gates Foundation established the [[COVID-19]] Therapeutics Accelerator to hasten the development and evaluation of new and repurposed drugs and biologics to treat patients for [[COVID-19]].<ref>{{Cite web |url=https://www.goodnewsnetwork.org/gates-foundation-commits-100-million-to-coronavirus-response/ |title=Gates Foundation Commits $100 Million to Speeding Up Coronavirus Treatments and Response |date=March 10, 2020 |website=Good News Network |language=en-US |access-date=March 15, 2020 |archive-date=March 11, 2020 |archive-url=https://web.archive.org/web/20200311031639/https://www.goodnewsnetwork.org/gates-foundation-commits-100-million-to-coronavirus-response/ |url-status=live }}</ref> After the [[World Health Organization]]'s appeal for funding, the Gates Foundation pledged an extra US$150 million on top of the US$100 million already committed earlier.{{cn|date=November 2024}}

By April 2020, the foundation had provided backing for six candidates for vaccines against COVID-19.<ref>{{Cite web |last=Varshney |first=Neer |date=2020-04-27 |title=Bill Gates, Backer of Inovio And Six Others, Says Coronavirus Vaccine Could Be Mass Produced Within A Year |url=https://finance.yahoo.com/news/bill-gates-backer-inovio-six-074230868.html |url-status=live |archive-url=https://archive.today/20220410093022/https://finance.yahoo.com/news/bill-gates-backer-inovio-six-074230868.html?guccounter=1 |archive-date=2022-04-10 |access-date=2022-06-14 |website=[[Yahoo! Finance]] |language=en-US}}</ref> In June, the foundation tapped the [[National University of Singapore]] to investigate which countries in [[Asia]] responded effectively to the pandemic.<ref>{{Cite web |date=June 2020 |title=National University of Singapore |url=https://www.gatesfoundation.org/about/committed-grants/2020/06/inv005598 |url-status=live |archive-url=https://archive.today/20220615022639/https://www.gatesfoundation.org/about/committed-grants/2020/06/inv005598 |archive-date=2022-06-15 |access-date=2022-06-15 |website=Bill & Melinda Gates Foundation |language=en}}</ref> On June 26, the foundation and its partners with the COVID-19 Therapeutics Accelerator announced the launch of the International COVID-19 Data Alliance (ICODA) to be hosted at Health Data Research UK.<ref>{{Cite web |date=2020-06-26 |title=COVID-19 Therapeutics Accelerator Donors Launch International Alliance to Connect Research Data Sources and Enable Collaboration |url=https://www.gatesfoundation.org/ideas/media-center/press-releases/2020/06/covid-19-therapeutics-accelerator-donors-launch-international-alliance |url-status=live |archive-url=https://web.archive.org/web/20210414083155/https://www.gatesfoundation.org/Ideas/Media-Center/Press-Releases/2020/06/COVID-19-Therapeutics-Accelerator-Donors-Launch-International-Alliance |archive-date=2021-04-14 |access-date=2022-10-01 |website=Bill & Melinda Gates Foundation |language=en}}</ref>

In December 2020, the foundation solicited applications for funding for researchers at [[McMaster University]] to develop [[epidemiological models]] for [[SARS-CoV-2]], as well as [[COVID-19 vaccine]]s, [[Covid-19 treatment|treatments]] and [[Non-pharmaceutical intervention (epidemiology)|non-pharmaceutical interventions]].<ref>{{Cite web |title=Bill & Melinda Gates Foundation: Grand Challenges ICODA COVID-19 Data Science |url=https://research.mcmaster.ca/funding/grand-challenges-icoda-covid-19-data-science-initiative/ |url-status=live |archive-url=https://archive.today/20211201212030/https://research.mcmaster.ca/funding/grand-challenges-icoda-covid-19-data-science-initiative/ |archive-date=2021-12-01 |access-date=2022-06-10 |website=[[McMaster University]] Research & Innovation |language=en-US}}</ref> The foundation re-upped its support of ICODA in May 2021 with a grant of $577,246.<ref>{{Cite web |date=May 2021 |title=Health Data Research UK |url=https://www.gatesfoundation.org/about/committed-grants/2021/05/inv033701 |url-status=live |archive-url=https://archive.today/20221001073727/https://www.gatesfoundation.org/about/committed-grants/2021/05/inv033701 |archive-date=2022-10-01 |access-date=2022-10-01 |website=Bill & Melinda Gates Foundation |language=en}}</ref>

In August 2021, the foundation awarded a $587,568 grant to Wits Health Consortium to test the effectiveness of the [[COVID-19 vaccine]]s distributed in [[South Africa]] by [[Johnson & Johnson]] and [[Pfizer]].<ref>{{Cite web |date=August 2021 |title=Wits Health Consortium (Pty) Ltd |url=https://www.gatesfoundation.org/about/committed-grants/2021/08/inv035995 |url-status=live |archive-url=https://web.archive.org/web/20211119093632/https://www.gatesfoundation.org/about/committed-grants/2021/08/inv035995 |archive-date=2021-11-19 |access-date=2022-06-14 |website=Bill & Melinda Gates Foundation |language=en}}</ref>

In November 2021, the foundation gave $2,118,334 to [[Providence Therapeutics]] to develop more cost-effective [[mRNA vaccine]]s.<ref>{{Cite web |date=November 2021 |title=Providence Therapeutics |url=https://www.gatesfoundation.org/about/committed-grants/2021/11/inv036094 |url-status=live |archive-url=https://archive.today/20220614010933/https://www.gatesfoundation.org/about/committed-grants/2021/11/inv036094 |archive-date=2022-06-14 |access-date=2022-06-14 |website=Bill & Melinda Gates Foundation |language=en}}</ref>